ArticleCurrent ophthalmology reports2019
Molecular Biomarkers for Glaucoma.
Article in Current ophthalmology reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 15 citations in OpenAlex.
- Comprehensive profiling of the human tear fluid miRNome using small RNA sequencing.The ocular surface · 2026Article
- Tear fluid database: a reference website for tear fluid proteomics.Database : the journal of biological databases and curation · 2026Article
- Ophthalmic drug discovery and development using artificial intelligence and digital health technologies.NPJ digital medicine · 2025Review
- Peripherex Home Visual Field Demonstrates High Test-Retest Reliability, Validity.Clinical ophthalmology (Auckland, N.Z.) · 2025Article
- Clinical Tear Fluid Proteomics-A Novel Tool in Glaucoma Research.International journal of molecular sciences · 2022Review
- Protein Biomarkers in Glaucoma: A Review.Journal of clinical medicine · 2021Review
- Candidate Glaucoma Biomarkers: From Proteins to Metabolites, and the Pitfalls to Clinical Applications.Biology · 2021Review
- Systemic Alterations of Immune Response-Related Proteins during Glaucoma Development in the Murine Model DBA/2J.Diagnostics (Basel, Switzerland) · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
purpose of reviewThis article summarizes the current studies on molecular biomarkers with potential implications in diagnosis, prognosis, and response to treatment in patients with glaucoma. RECENT
findingsImportant advances have occurred in the understanding of the pathogenesis of glaucomatous neurodegeneration. Protein biomarkers associated with inflammatory, neurodegenerative, and other molecular pathways have been described in glaucoma patients in tear film, aqueous fluid, vitreous fluid, and serum, however, we are still far from having a clear picture of the whole molecular network that relates to the disease and its implications in clinical use. SUMMARY: Although more studies are needed, current and emerging molecular biomarkers candidates in glaucoma may eventually transition into clinical use and contribute to outline the concept of precision medicine and precision health in glaucoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.